Literature DB >> 33992787

Substituting Cannabidiol for Opioids and Pain Medications Among Individuals With Fibromyalgia: A Large Online Survey.

Kevin F Boehnke1, Joel J Gagnier2, Lynne Matallana3, David A Williams2.   

Abstract

People report substituting cannabis for pain medications, but whether cannabidiol (CBD) is used similarly remains unknown. CBD products can be CBD alone (isolate), hemp extract (containing <0.3% Δ-9-tetrahydrocannabinol [THC], other cannabinoids, and terpenes), or CBD-cannabis (containing >0.3% THC). In a secondary analysis from a cross-sectional survey, we examined substitution patterns among n = 878 individuals with fibromyalgia who currently used CBD. We sub-grouped participants by most commonly used CBD product (CBD isolate, hemp, CBD-cannabis, no preference) and whether they substituted CBD for medications. We investigated rationale for substituting, substitution-driven medication changes, CBD use patterns, and changes in pain-related symptoms (eg, sleep, anxiety). The study population was 93.6% female and 91.5% Caucasian, with an average age of 55.5 years. The majority (n = 632, 72.0%) reported substituting CBD products for medications, most commonly NSAIDs (59.0%), opioids (53.3%), gabapentanoids (35.0%), and benzodiazepines (23.1%). Most substituting participants reported decreasing or stopping use of these pain medications. The most common reasons for substitution were fewer side effects and better symptom management. Age, hemp products, past-year use of marijuana, and higher somatic burden were all associated with substituting (P's ≤ .05). Those who substituted reported larger improvements in health and pain than those who did not. Participants using CBD-cannabis reported significantly more substitutions than any other group (P's ≤ .001) and larger improvements in health, pain, memory, and sleep than other subgroups. This widespread naturalistic substitution for pain medications suggests the need for more rigorous study designs to examine this effect. PERSPECTIVE: This article shows that people with fibromyalgia are deliberately substituting CBD products for conventional pain medications despite the dearth of evidence suggesting CBD products may be helpful for fibromyalgia. CBD's medication-sparing and therapeutic potential should be examined in more rigorous study designs.
Copyright © 2021 United States Association for the Study of Pain, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cannabidiol; Fibromyalgia; Hemp; Opioids; Substitution

Mesh:

Substances:

Year:  2021        PMID: 33992787      PMCID: PMC8578153          DOI: 10.1016/j.jpain.2021.04.011

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  46 in total

1.  Cannabidiol Use for Fibromyalgia: Prevalence of Use and Perceptions of Effectiveness in a Large Online Survey.

Authors:  Kevin F Boehnke; Joel J Gagnier; Lynne Matallana; David A Williams
Journal:  J Pain       Date:  2021-01-02       Impact factor: 5.820

2.  The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis.

Authors:  A M Malfait; R Gallily; P F Sumariwalla; A S Malik; E Andreakos; R Mechoulam; M Feldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

3.  Antecedent nonbladder syndromes in case-control study of interstitial cystitis/painful bladder syndrome.

Authors:  John W Warren; Fred M Howard; Raymond K Cross; Janine L Good; Myrna M Weissman; Ursula Wesselmann; Patricia Langenberg; Patty Greenberg; Daniel J Clauw
Journal:  Urology       Date:  2008-11-08       Impact factor: 2.649

4.  Functional somatic syndromes: sensitivities and specificities of self-reports of physician diagnosis.

Authors:  John W Warren; Daniel J Clauw
Journal:  Psychosom Med       Date:  2012-10-15       Impact factor: 4.312

5.  Prognostic factors for recent-onset interstitial cystitis/painful bladder syndrome.

Authors:  John W Warren; Daniel J Clauw; Patricia Langenberg
Journal:  BJU Int       Date:  2012-08-09       Impact factor: 5.588

Review 6.  Fibromyalgia: a clinical review.

Authors:  Daniel J Clauw
Journal:  JAMA       Date:  2014-04-16       Impact factor: 56.272

7.  The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities.

Authors:  Dixon H Xu; Benjamin D Cullen; Meng Tang; Yujiang Fang
Journal:  Curr Pharm Biotechnol       Date:  2020       Impact factor: 2.837

Review 8.  Cannabidiol Interactions with Medications, Illicit Substances, and Alcohol: a Comprehensive Review.

Authors:  Premalatha Balachandran; Mahmoud Elsohly; Kevin P Hill
Journal:  J Gen Intern Med       Date:  2021-01-29       Impact factor: 6.473

9.  Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials.

Authors:  Emma Fisher; R Andrew Moore; Alexandra E Fogarty; David P Finn; Nanna B Finnerup; Ian Gilron; Simon Haroutounian; Elliot Krane; Andrew S C Rice; Michael Rowbotham; Mark Wallace; Christopher Eccleston
Journal:  Pain       Date:  2021-07-01       Impact factor: 6.961

10.  Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis.

Authors:  Holly T Philpott; Melissa O'Brien; Jason J McDougall
Journal:  Pain       Date:  2017-12       Impact factor: 7.926

View more
  5 in total

Review 1.  Cannabis-Based Medicines and Medical Cannabis in the Treatment of Nociplastic Pain.

Authors:  Mary-Ann Fitzcharles; Frank Petzke; Thomas R Tölle; Winfried Häuser
Journal:  Drugs       Date:  2021-11-20       Impact factor: 9.546

Review 2.  Cannabidiol (CBD) in Rheumatic Diseases (Musculoskeletal Pain).

Authors:  Kevin F Boehnke; Winfried Häuser; Mary-Ann Fitzcharles
Journal:  Curr Rheumatol Rep       Date:  2022-05-03       Impact factor: 4.686

3.  A mixed methods analysis of cannabis use routines for chronic pain management.

Authors:  Kevin F Boehnke; Laura Yakas; J Ryan Scott; Melissa DeJonckheere; Evangelos Litinas; Suzanne Sisley; Daniel J Clauw; David A Williams; Jenna McAfee
Journal:  J Cannabis Res       Date:  2022-01-11

4.  A "Good" Smoke? The Off-Label Use of Cannabidiol to Reduce Cannabis Use.

Authors:  Davide Fortin; Vincent Di Beo; Sophie Massin; Yann Bisiou; Patrizia Carrieri; Tangui Barré
Journal:  Front Psychiatry       Date:  2022-03-17       Impact factor: 4.157

5.  Cannabidiol Product Dosing and Decision-Making in a National Survey of Individuals with Fibromyalgia.

Authors:  Kevin F Boehnke; Joel J Gagnier; Lynne Matallana; David A Williams
Journal:  J Pain       Date:  2021-06-30       Impact factor: 5.820

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.